1. Immune-Based Therapies for Traumatic Brain Injury: Insights from Pre-Clinical Studies
- Author
-
Amanda S. de Miranda, Thiago Macedo e Cordeiro, Aline Silva de Miranda, Antônio Lúcio Teixeira, Rodrigo Novaes Ferreira, Caroline Amaral Machado, Leonardo Cruz de Souza, and Ana Cristina Simões e Silva
- Subjects
medicine.medical_specialty ,Traumatic brain injury ,Anti-Inflammatory Agents ,Context (language use) ,Biochemistry ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Brain Injuries, Traumatic ,Drug Discovery ,medicine ,Animals ,Humans ,Young adult ,Child ,Intensive care medicine ,030304 developmental biology ,Cause of death ,Pharmacology ,0303 health sciences ,business.industry ,Research ,Organic Chemistry ,medicine.disease ,Molecular Medicine ,business ,030217 neurology & neurosurgery - Abstract
Traumatic Brain Injury (TBI) is a major public health problem. It is the leading cause of death and disability, especially among children and young adults. The neurobiology basis underlying TBI pathophysiology remains to be fully revealed. Over the past years, emerging evidence has supported the hypothesis that TBI is an inflammatory based condition, paving the way for the development of potential therapeutic targets. There is no treatment capable to prevent or minimize TBIassociated outcomes. Therefore, the search for effective therapies is a priority goal. In this context, animal models have become valuable tools to study molecular and cellular mechanisms involved in TBI pathogenesis as well as novel treatments. Herein, we discuss therapeutic strategies to treat TBI focused on immunomodulatory and/or anti-inflammatory approaches in the pre-clinical setting.
- Published
- 2020
- Full Text
- View/download PDF